BrightSpring Health Services, Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. BrightSpring Health Services, Inc. is a leading home and community-based healthcare platform operating two reportable segments: Pharmacy Solutions and Provider Services. The quarter was defined by a major strategic shift: the divestiture of the Community Living business, which was classified as discontinued operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $3,613.7 million | $2,878.1 million |
| Net Income (Continuing Ops) | $74.3 million | $9.2 million |
| Net Income (Total) | $148.6 million | $29.0 million |
| Diluted EPS (Continuing Ops) | $0.34 | $0.05 |
| Adjusted EBITDA | $189.8 million | $131.1 million |
| Cash and Equivalents | $888.8 million | $52.6 million |
| Total Debt (Gross) | $2,557.4 million | $2,569.7 million |
| Company Leverage Ratio | 2.27x | 2.99x (Dec 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased by 25.6% ($735.6 million) year-over-year. Pharmacy Solutions grew 25.2% to $3.2 billion, while Provider Services grew 27.9% to $442.4 million.
- Profitability Surge: Net income from continuing operations jumped 707% to $74.3 million, driven by a 42.5% increase in gross profit and a 7.5% decrease in net interest expense.
- Divestiture Impact: The sale of the Community Living business closed on March 30, 2026, generating $810.9 million in cash proceeds and a pre-tax gain of $103.4 million. This transaction significantly boosted total net income and cash balances.
- Acquisition Activity: The Company completed the acquisition of 107 branches from Amedisys and LHC Group in late 2025/early 2026, contributing $78.5 million in revenue to the Provider Services segment in Q1 2026.
- Liquidity: Cash and cash equivalents increased from $88.4 million to $888.8 million, primarily due to divestiture proceeds.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the strategic focus on Senior and Specialty populations following the divestiture. The streamlined portfolio is expected to drive operational efficiencies and exposure to high-growth markets like home health and hospice. The Company repurchased 1.46 million shares for $60.0 million in connection with a secondary offering by selling stockholders.
Risks and Contingencies:
- Regulatory & Reimbursement: Significant reliance on Medicare and Medicaid reimbursement rates; potential impacts from the Inflation Reduction Act on drug pricing and federal spending.
- Operational: Labor shortages and wage inflation in the healthcare sector; integration risks from recent acquisitions.
- Financial: Substantial indebtedness ($2.56 billion) and exposure to variable interest rates, partially mitigated by $1.5 billion in interest rate swaps.
Investor Verification Checklist
- Divestiture Accounting: Verify the classification of the Community Living business as discontinued operations and the sustainability of earnings without this segment.
- Pharmacy Mix Shift: Confirm the sustainability of the 27.0% increase in revenue per script, driven by specialty drug volume, amidst Inflation Reduction Act headwinds.
- Acquisition Integration: Assess the performance of the newly acquired Amedisys/LHC branches and the timeline for remaining branch closings.
- Debt Covenants: Review the First Lien Credit Agreement covenants, specifically the leverage ratio (currently 2.27x) and interest coverage, given the high debt load.
- TEU Settlement: Monitor the 8 million Tangible Equity Units (TEUs) maturing in February 2027 and their potential dilutive impact on share count.